Clinical features of metamizole intolerant patients with/without bronchial asthma Source: Eur Respir J 2002; 20: Suppl. 38, 422s Year: 2002
Effect of mepolizumab on chronic rhinosinusitis symptoms and nasal hypersensitivity in patients with or without nasal polyps Source: Virtual Congress 2020 – Asthma management: role of biomarkers and comorbidities Year: 2020
Nasal polyposis, analgesics intolerance and asthma Source: Eur Respir J 2001; 18: Suppl. 33, 428s Year: 2001
Impact of biologic therapy in severe asthma with nasal polyps Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021
Impact of mepolizumab in severe asthma with nasal polyps Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021
Additive effect of Zafirlukast in combination with Mometason furoate in treatment of Nasal polyps in patients with mild persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 372s Year: 2003
Mepolizumab reduces nasal symptoms in asthmatic patients with chronic rhino-sinusitis and nasal polyposis: a 12 months real-life study Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020
Tezepelumab efficacy in patients with severe, uncontrolled asthma and comorbid nasal polyps in NAVIGATOR Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021
Characterization of omalizumab partitioning in the nasal mucosa of patients Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019
Treatment of nasal polyposis in aspirine sensitive asthma Source: Eur Respir J 2001; 18: Suppl. 33, 425s Year: 2001
Comparative effects of Mometason furoate and Zafirlukast in treatment of nasal polyps in asthmatic patients Source: Eur Respir J 2002; 20: Suppl. 38, 45s Year: 2002
The impact of targeted therapy in children with uncontrolled allergic persistent severe asthma and nasal polyps Source: International Congress 2017 – Paediatric asthma: therapies and comorbidities Year: 2017
Dupilumab reduces blood and nasal biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps with and without comorbid asthma: SINUS-52 trial Source: Virtual Congress 2020 – Phenotypes of asthma and COPD Year: 2020
Differential treatment response to mepolizumab in severe eosinophilic asthma with nasal polyps Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020
Mycobiota of the pharynx in patients with persistent bronchial asthma who constantly applying the inhaled corticosteroids Source: Annual Congress 2012 - Asthma: assessment and treatment Year: 2012
Response of children with bronchial asthma to combined therapy with an oral immunostimulating drug and antileukotrienes Source: Eur Respir J 2005; 26: Suppl. 49, 159s Year: 2005
Patient characteristics and treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in Canada Source: Virtual Congress 2021 – Clinical features and new biomarkers of asthma, COPD and chronic cough Year: 2021
Nasal mucosa biopsy in patients with severe bronchial asthma Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009
Tolerance test for inhaled antibiotics in patients with chronic bronchial infection Source: International Congress 2018 – The airway microbiome across the spectrum of airway disease Year: 2018
Tolerance to COX-2 inhibitors in patients intolerant to aspirin: challenge mandatory Source: Eur Respir J 2003; 22: Suppl. 45, 547s Year: 2003